The First Human Trial of Epigenetic Reprogramming Has Begun. Here's What You Need to Know.

For the first time, doctors are testing whether they can safely turn back the clock inside human cells. The therapy, called ER-100, isn't a pill or a traditional drug—it's a one-time gene therapy designed to partially reprogram cells in the eye to a more youthful state. If successful, it could lay the foundation for a new class of medicine that treats the underlying biology of aging, not just its symptoms.

The U.S. Food and Drug Administration cleared the way for this landmark study on January 28, 2026, marking the first clinical trial of its kind in the world .

What Is ER-100 and How Does It Work?

ER-100 is a gene therapy developed by Life Biosciences, a Boston-based biotech company co-founded by Harvard geneticist David Sinclair . The treatment is built on Nobel Prize-winning research into cellular reprogramming but uses a much more precise and controlled approach.

The 'Partial' Reprogramming Approach

In 2006, Shinya Yamanaka discovered that introducing four specific genes into an adult cell could rewind it all the way back to an embryonic-like stem cell. While revolutionary, this full reset is too dangerous for a living person—it erases a cell's identity and can cause tumors called teratomas.

ER-100 takes a far more cautious route. Instead of four genes, it only uses three: OCT4, SOX2, and KLF4 (OSK). The fourth factor, c-MYC, is deliberately omitted because it's strongly linked to cancer .

By expressing these three factors only transiently, the therapy aims to clean up the "epigenetic noise" that accumulates with age and damage—restoring youthful patterns of gene expression without wiping a cell's identity. Think of it less like demolishing a building and more like restoring the original operating system .

The 'Off-Switch' for Safety

A key innovation is the therapy's safety switch. The OSK genes are controlled by a doxycycline-inducible (Tet-On) system . Patients in the trial take the common oral antibiotic doxycycline, which acts as a molecular key to turn on the reprogramming genes. If an unexpected safety issue arises, the patient can simply stop taking the antibiotic, and the reprogramming process halts immediately.

This external layer of control was a critical feature for regulators, addressing the primary fear of uncontrolled cellular growth. As a company executive explained, "If there are any safety issues, we can simply turn it off" .

The Phase 1 Trial: Safety First

This is a small, first-in-human test. The primary goal is not to cure blindness—at least not yet—but to answer a more fundamental question: is this safe?

• Trial ID: NCT07290244, listed on ClinicalTrials.gov
• Conditions: The study enrolls adults with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), sometimes called an "eye stroke." Both conditions involve irreversible damage to retinal ganglion cells (RGCs), the neurons that carry visual information from the eye to the brain. Currently, there are no treatments that can restore these cells once lost .
• Administration: Participants receive a single intravitreal injection of an AAV2 viral vector directly into one eye. The modified virus delivers the OSK genes to the targeted RGCs .
• Primary Endpoint: Safety and tolerability. Researchers will closely monitor for any adverse effects.
• Secondary Endpoints: The trial will also measure immune responses and conduct exploratory assessments of visual function to gather early signals of whether the therapy works .
• Timeline: The first patient was dosed in April 2026 at a clinical site in the Greater Boston area .

A Milestone Funded by a New Wave of Scientific Optimism

The trial's launch was fueled by a surge of investor confidence in longevity science. On April 8, 2026, Life Biosciences closed a fully subscribed $80 million Series D financing round. This capital is expected to fund the entire Phase 1 study and extend the company's operations into 2027 .

An industry observer noted that this latest round brings the company's cumulative total disclosed funding to over $240 million . While this figure is based on public statements and has not been independently verified in official filings, earlier confirmed rounds—including an $82 million Series C in 2022 and a prior $158 million cumulative total—support a fundraising history in this range . The financing reflects strong interest in the broader partial epigenetic reprogramming (PER) platform, which the company is also developing for metabolic-associated steatohepatitis (MASH), a liver disease .

Why This Trial Matters Beyond the Eye

For the longevity research community, the ER-100 trial is a critical moment of truth.

For over a decade, animal studies have produced stunning results. In one often-cited 2020 study, researchers used a similar OSK-based gene therapy to restore vision in mice with glaucoma or age-related vision loss. In non-human primates, Life Biosciences' preclinical work reportedly showed a near-complete recovery of retinal ganglion cell electrical function after optic nerve injury .

But animals are not humans. The Phase 1 trial is the first real-world test of the central hypothesis underlying the entire field: that aging is not just a wear-and-tear process, but a modifiable epigenetic program that can be safely nudged backward. A positive safety and efficacy signal would validate decades of foundational science and accelerate development for other age-related diseases. The FDA does not currently recognize aging as a disease, so the trial is targeting specific optic nerve conditions under existing regulatory frameworks . Still, the implications are far broader. Success here could pave the way for epigenetic reprogramming therapies in the liver, muscles, and other tissues where damage from aging accumulates .